Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Sells $98,481.90 in Stock

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now owns 9,574 shares in the company, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ:JAZZ opened at $133.35 on Thursday. The firm has a market cap of $7.74 billion, a P/E ratio of 10.89, a price-to-earnings-growth ratio of 1.13 and a beta of 1.14. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. The company has a 50-day simple moving average of $138.34. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $176.73.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.16 by $0.49. The company had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.49 EPS. Research analysts predict that Jazz Pharmaceuticals PLC will post 13.41 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Bank of Hawaii bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $447,000. Victory Capital Management Inc. lifted its stake in Jazz Pharmaceuticals by 479.4% in the second quarter. Victory Capital Management Inc. now owns 104,670 shares of the specialty pharmaceutical company’s stock valued at $14,922,000 after purchasing an additional 86,606 shares during the last quarter. UBS Asset Management Americas Inc. lifted its stake in Jazz Pharmaceuticals by 0.7% in the second quarter. UBS Asset Management Americas Inc. now owns 359,162 shares of the specialty pharmaceutical company’s stock valued at $51,202,000 after purchasing an additional 2,483 shares during the last quarter. California State Teachers Retirement System lifted its stake in Jazz Pharmaceuticals by 0.3% in the second quarter. California State Teachers Retirement System now owns 94,397 shares of the specialty pharmaceutical company’s stock valued at $13,457,000 after purchasing an additional 305 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Jazz Pharmaceuticals by 13.8% in the second quarter. Morgan Stanley now owns 283,210 shares of the specialty pharmaceutical company’s stock valued at $40,373,000 after purchasing an additional 34,451 shares during the last quarter. 89.59% of the stock is currently owned by institutional investors.

JAZZ has been the topic of several recent research reports. ValuEngine raised Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 8th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday. HC Wainwright reaffirmed a “hold” rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Finally, Piper Jaffray Companies set a $202.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $176.53.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Fundamental Analysis

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate CryoPort Inc  Will Post Quarterly Sales of $9.50 Million
Brokerages Anticipate CryoPort Inc Will Post Quarterly Sales of $9.50 Million
Wintrust Financial Corp  Expected to Post Quarterly Sales of $374.16 Million
Wintrust Financial Corp Expected to Post Quarterly Sales of $374.16 Million
Zacks: Brokerages Expect Greenbrier Companies Inc  to Announce $1.39 Earnings Per Share
Zacks: Brokerages Expect Greenbrier Companies Inc to Announce $1.39 Earnings Per Share
Zacks: Brokerages Expect Greenbrier Companies Inc  Will Post Quarterly Sales of $956.82 Million
Zacks: Brokerages Expect Greenbrier Companies Inc Will Post Quarterly Sales of $956.82 Million
Zacks: Analysts Expect Varex Imaging Corp  Will Announce Quarterly Sales of $202.49 Million
Zacks: Analysts Expect Varex Imaging Corp Will Announce Quarterly Sales of $202.49 Million
Brokerages Anticipate Varex Imaging Corp  Will Post Earnings of $0.46 Per Share
Brokerages Anticipate Varex Imaging Corp Will Post Earnings of $0.46 Per Share


© 2006-2019 Ticker Report